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Abstract
Objectives. To estimate the costs, benefits and cost-effectiveness of vaccination for ro-
tavirus gastroenteritis in eight Latin American and Caribbean countries: Argentina, Brazil,
Chile, the Dominican Republic, Honduras, Mexico, Panama, and Venezuela. 
Methods.An economic model was constructed to estimate the cost-effectiveness of vaccina-
tion from the health care system perspective, using national administrative and published epidemiological 
evidence, country-specific cost estimates, and vaccine efficacy data. The model was applied to the first five 
years of life for the 2003 birth cohort in each country. The main health outcome was the disability-adjusted 
life year (DALY), and the main summary measure was the incremental cost per DALY averted. A 3% 
discount rate was used for all predictedmcosts and benefits. Sensitivity analyses evaluated the impact of 
uncertainty regarding key variables on cost-effectiveness estimates. 
Results. According to the estimates obtained with the economic model, vaccination would
prevent more than 65% of the medical visits, deaths, and treatment costs associated with rota-virus 
gastroenteritis in the eight countries analyzed here. At a cost of US$  24 per course (for a two-dose 
vaccine), the incremental cost-effectiveness ratio ranged from US$  269/DALY in Honduras to US$  10 
656/DALY in Chile. Cost-effectiveness ratios were sensitive to assumptions about vaccine price, mortality, 
and vaccine efficacy. 
Conclusions Vaccination would effectively reduce the disease burden and health care costs
of rotavirus gastroenteritis in the Latin American and Caribbean countries analyzed here.
From the health care system perspective, universal vaccination of infants is predicted to be
cost-effective, based on current standards.
Richard D. Rheingans, Dagna Constenla, Lynn Antil, Bruce L. Innis, and Thomas Breuer (2007) 
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Rotavirus infection, the single most
important cause of gastroenteritis,
leads to dehydration and death in
small children in developed and de-
veloping countries (1, 2). Gastroin-
testinal infections in children have a
wide range of impacts on their fami-
lies and society, including increased
medical expenditures, lost productiv-
ity, other costs to households for the
care of children, and pain and suffer-
ing caused to children and their fami-
lies. Universal vaccination of infants
with an effective rotavirus vaccine
would likely reduce the incidence of
moderate and severe gastroenteritis,
as well as its burden on families and
society. 
A previous study estimated that ro-
tavirus gastroenteritis is responsible
for more than 15 000 deaths in chil-
dren under 5 years of age in Latin
America (1). In addition, several stud-
ies in Latin America have documented
that rotavirus gastroenteritis is a com-
mon cause of hospitalization in chil-
dren under 5 years of age (1–7). Rota-
virus has also been shown to generate
substantial economic costs for the
health care system and society as a
whole (6, 8). Cost-effectiveness studies
elsewhere suggest that vaccination
may be a cost-effective strategy for
reducing this health and economic
burden (9, 10).
The main impact of rotavirus gas-
troenteritis is the morbidity and mor-
tality it causes in children, and infor-
mation on the economic burden of
disease and the cost-effectiveness of
vaccination can aid decisionmakers in
choosing interventions to improve
health. Effective vaccines are now
available for preventing rotavirus gas-
troenteritis (11, 12), but investments 
in medical advances such as new vac-
cines compete against other interven-
tions for health sector resources. Infor-
mation about the cost-effectiveness of
vaccination provides an estimate of the
health benefits resulting from the in-
vestment in vaccination, and such esti-
mates can then be compared to the po-
tential benefits of other interventions.
The objective of this analysis is to
provide an estimate of the cost-
effectiveness of universal rotavirus vac-
cination in eight Latin American and
Caribbean countries. The estimates
were developed using a spreadsheet-
based decision-analytic model popu-
lated with a combination of country-
specific data and estimates extrapolated
from other countries for which data
were lacking. Simulation techniques
were used to develop ranges for these
estimates, and to identify key data
needs. In order to characterize vacci-
nation benefits, the model used sec-
ondary data on the efficacy of Rotarix
(GlaxoSmithKline Biologicals, Rixen-
sart, Belgium), a live attenuated mono-
valent human rotavirus vaccine ad-
ministered orally to infants at 2 and 4
months of age (11). 
METHODS
Model overview
A decision-analytic model was devel-
oped using Excel software to estimate
the economic burden of rotavirus gas-
troenteritis and the cost-effectiveness of
vaccination in eight countries: Argen-
tina, Brazil, Chile, the Dominican Re-
public, Honduras, Mexico, Panama,
and Venezuela. These countries were
selected because they comprise a large
proportion of the population in Latin
America and the Caribbean, and the
eight nations also represent varying
geographic areas, health standards,
and income levels. They were also part
of a related project to characterize the
economic burden of disease in repre-
sentative Latin American countries (8).
The model estimated the expected
health outcomes and costs associated
with rotavirus gastroenteritis, and the
events and costs that might be averted
with vaccination of an annual birth co-
hort of children during the first five
years of their life in each country (8).
The principal inputs in the model in-
cluded epidemiological information
on disease incidence, health care costs
associated with different types of
cases, and the effectiveness and cost of
vaccination. 
The validity of the model was tested
in several ways. The initial model was
reviewed by a group of external ex-
perts convened by the Centers for
Disease Control and Prevention and
the Rotavirus Vaccine Program in Ge-
neva, Switzerland, in February 2004.
The predictive validity was assessed
through a structured comparison to 
an independent alternative rotavirus
cost-effectiveness model at a second
meeting held in March 2006. Internal
validity was also checked by testing
the results obtained when extreme val-
ues were used in the model.
The primary perspective for this
analysis was the health care system,
which we analyzed in terms of direct
medical costs associated with medical
treatment in formal inpatient and out-
patient settings. Direct medical costs
included the costs of diagnostic tests,
medication, supplies, facilities, and
personnel needed for treatment, but
excluded costs such as nonmedical
costs to households, costs of informal
medical treatment, or productivity
losses to caregivers. The main health
outcome measure was the disability-
adjusted life year (DALY). Rotavirus
vaccination was compared to current
practice (no universal vaccination and
current use of oral rehydration ther-
apy). All estimates were based on the
expected events and costs for the 2003
annual birth cohort until 5 years of
age. Estimates were expressed in 2003
US$. All future costs and DALY esti-
mates were discounted at a rate of 3%. 
Rotavirus disease and economic
burden
For each country, the disease bur-
den was estimated as the expected
number of rotavirus-associated events
(hospitalizations, outpatient visits,
and deaths) during the first five years
of life for the 2003 birth cohort. The
risk of rotavirus-related hospitaliza-
tion, outpatient visit, and death are
based on the cumulative risk of each
event due to acute gastroenteritis by
the age of 5 years, and the proportion
of these events attributed to rotavirus.
A detailed explanation of the methods
used to estimate disease burden can
be found in Rheingans et al. (8). Esti-
mates of the number of events were
based on the size of the birth cohort
and the estimated age distribution of
each event. 
Disease burden was also estimated
in terms of DALYs. This aggregate
measure makes it possible to compare
outcomes for other diseases and inter-
ventions by quantifying the years of
life lost (YLLs) due to premature mor-
tality, and the years lived with disabil-
ity (YLDs) (13). The average country-
specific life expectancies at birth and 
1 year of age (14) were used to calcu-
late YLLs. Only morbidity from dis-
ease severe enough to require medical
care was considered to calculate YLDs.
Estimates for years lived with disabil-
ity were calculated with default dis-
ability weights from the Global Bur-
den of Disease Study (13), the World
Health Organization (WHO) guide-
lines for cost-effectiveness studies (15),
and an estimated duration of illness of
six days (16). For rotavirus gastroen-
teritis, the DALYs were almost entirely
based on the YLLs because disability
from rotavirus infections is usually
brief. A discount rate of 3% and age
weighting were included to ensure
comparability (15). 
The economic burden of rotavirus
gastroenteritis for each country was
estimated by combining estimates of
the number of each type of event with
information on the costs associated
with the event. Country-specific esti-
mates of direct medical costs, nonmed-
ical direct costs, and productivity
losses were developed for hospital and
outpatient rotavirus events. For a com-
plete description of the methods used
to calculate the economic burden, see
Rheingans et al. (8). 
Vaccination effectiveness and costs
Vaccine efficacy from clinical trials
provides an upper-bound estimate of
the potential effectiveness in real world
situations. In order to estimate the ef-
fectiveness of vaccination, we also con-
sidered information on the expected
coverage, timing of illness, and the ef-
fectiveness of vaccination against dif-
ferent outcomes. The temporal pattern
of these parameters must be consid-
ered since vaccination can only affect
events that would have occurred after
the vaccine was received. A decision-
analytic model was developed to com-
bine information on disease burden,
coverage, and effectiveness in a tempo-
rally explicit fashion.
The age distribution of disease was
estimated for each of the key rotavirus
outcomes (death, hospitalization, and
outpatient visits) on the basis of pub-
lished studies (4, 5, 7, 16–23). The esti-
mated total number of events for the
annual birth cohort was then divided
into the following age categories: 0–2
months, 3–5 months, 6–8 months, 9–11
months, 12–23 months, 24–35 months,
36–47 months, and 48–59 months. 
Next, the model considered the ex-
pected immunization status of chil-
dren in each age category. It was as-
sumed that the timing of the two-dose
rotavirus vaccine would correspond to
the delivery of the first and second
diphtheria, pertussis, and tetanus
(DPT) doses at 2 and 4 months of age.
In the baseline analysis, national cov-
erage of rotavirus vaccination was
based on DPT3 coverage at 1 year of
age for the year 2003, which ranged
from 65% in the Dominican Republic
to 99% in Chile (24, 25). Because ro-
tavirus vaccination would occur with
DPT doses one and two, but standard-
ized coverage data are available only
for the third DPT dose, this approach
may underestimate the proportion of
children who would receive both rota-
virus vaccine doses. In addition, it was
assumed that all children would re-
ceive the vaccine at the recommended
time. 
Information on the efficacy of the
Rotarix two-dose vaccine against clini-
cal trial endpoints was converted to
efficacy against epidemiologically rel-
evant outcomes. Ruiz-Palacios and
colleagues reported the efficacy for
hospitalization from severe rotavirus
gastroenteritis as 85% during the first
year (11). Efficacy against rotavirus
gastroenteritis resulting in outpatient
visits was estimated as the reported
mean of the efficacy against severe
(85%) (11) and any (70%) (26) rotavirus
gastroenteritis. Clinical trial data in
Latin America have shown that vac-
cine efficacy increases with disease
severity (26), and it was assumed that
efficacy against mortality would be the
same as efficacy against hospitaliza-
tion. For the baseline analysis it was
further assumed that one dose of the
vaccine would have the same effec-
tiveness as a full course during the
inter-dosing period, as demonstrated
in a clinical trial in Latin America (27). 
The effectiveness of vaccination was
estimated by following the 2003 birth
cohort through the age periods identi-
fied above, to the age of 5 years. The
predicted reduction in the number of
hospitalizations, outpatient visits, and
deaths during this period was esti-
mated based on vaccine coverage and
efficacy.
Calculations of cost-effectiveness
also require estimates of vaccination
costs. For this analysis, these costs in-
cluded the cost of administration, the
price of the vaccine, the number of
doses given (based on coverage level),
and expected losses from waste (as-
sumed to be 10%). Administrative
costs consist of the cost of health per-
sonnel and training, cold chain main-
tenance, storage space, and public ed-
ucation. No costs for adverse events
were included, since the safety profile
of the vaccine is no different from that
of a placebo (11, 27). The analysis as-
sumed that the rotavirus vaccine
would be administered along with the
current Expanded Program on Immu-
nization (EPI) vaccines; therefore, in-
cremental administrative costs would
be low. Earlier studies estimated the
cost of immunization for current EPI
vaccines (28–31); however, there were
no data on the incremental cost of
adding a vaccine to the current EPI
regimen. Based on the range of esti-
mates in previous immunization cost
studies and the assumption of low in-
cremental costs, the model assumed
an administration cost of US$ 1.00 per
course. Given that the actual price was
unknown, vaccine cost was assumed
to be US$ 24 per course for the two-
dose vaccine, and alternative values
were used in the sensitivity analysis. 
Cost-effectiveness analysis
The cost-effectiveness summary
measure was the net cost per DALY
averted (US$/DALY). All costs are re-
ported in 2003 US$. From the health
care system perspective, net costs are
defined as the cost of vaccination (ad-
ministration and vaccine itself) minus
the averted medical costs. Averted
DALYs were calculated as the differ-
ence between the health burden with-
out vaccination and the health burden
with vaccination. The incremental
cost-effectiveness ratio (ICER) is the
ratio of the net costs to the net health
benefits (US$/DALY). This ratio rep-
resents the net investment required to
avert one DALY; thus, a lower ICER
implies greater cost-effectiveness. The
net cost per death averted was also
calculated.
Several standards can be used to
determine whether an intervention is
cost-effective in terms of US$/DALY.
The appropriateness of the different
approaches depends on the perspec-
tive of the decisionmaker. The results
presented here for rotavirus vaccina-
tion are intended to estimate cost-
effectiveness from the health care
perspective. The World Health Report
2002 suggests that “very cost-effective
interventions” are those that “avert 
each additional DALY at a cost less
than GDP [gross domestic product]
per capita.” In addition, the WHO
considers interventions with a cost-
effectiveness ratio (US$/DALY) be-
tween one and three times the per
capita GDP as cost-effective (32). 
In addition to the ICER, break-even
price was calculated as a secondary
outcome measure. The break-even
price for each country was calculated
as the price per course for which the
cost of vaccination (procurement and
delivery) equaled the expected cost
savings to the health care system.
Sensitivity and uncertainty analyses
The model described above re-
quired country-specific data on the
epidemiology of the disease, the costs
associated with different outcomes,
and vaccine effectiveness. Although
some of these data were available, the
quality and relevance were limited for
others. These data limitations create
uncertainties regarding the final esti-
mates of costs and cost-effectiveness.
Two approaches were used to address
this uncertainty: sensitivity and uncer-
tainty analyses. 
A one-way sensitivity analysis was
conducted to assess the impact of
changes in individual parameters on
the ICER for each country, and to as-
sess the robustness of the analysis. The
variables included in this analysis
were incidence of hospitalization, out-
patient visits, and death from rota-
virus gastroenteritis; costs associated
with different events; vaccine efficacy;
and vaccine price. 
An uncertainty analysis was con-
ducted to evaluate the overall impact
of these uncertainties on quantitative
estimates, and to assess the need for
additional data collection. A Monte
Carlo model was developed based on
the model of rotavirus disease burden
and vaccination cost-effectiveness de-
scribed above. In Monte Carlo analy-
sis, individual point estimates of para-
meters are replaced with distributions
of potential values (33). In a series of it-
erations, individual values are ran-
domly selected from each of the distri-
butions, and the results are calculated
and stored. The process is repeated for
a large number of iterations (10 000 in
this case). The final product is a distri-
bution of potential outcomes that de-
scribe the likely range of actual ex-
pected results. 
For national disease burden vari-
ables, distributions were used to char-
acterize the cumulative incidence of
illness outcomes (hospitalization, out-
patient visits, and death) in each
country, and the proportion of each
outcome due to rotavirus. The distri-
butions specified a range around the
value chosen for the analysis, and de-
scribed the likelihood that the value
chosen was representative of the true
population value. Wider distributions
were used for countries for which the
estimates were extrapolated from for-
eign data. For cost variables, distribu-
tions were based on the cost estimates
presented in Rheingans et al. (8). For
estimates of vaccine effectiveness, dis-
tributions were used for efficacy (in
protecting against rotavirus hospital-
ization, outpatient visits, and mortal-
ity), based on the reported confidence
intervals from clinical trials (11, 26).
Distributions were also included for
the reduction in efficacy from using
only one dose, and the reduction in ef-
ficacy during subsequent seasons.
Table 1 summarizes the best estimates
and distributions used in the analysis,
including location parameters. 
Uncertainty limits (5% and 95%) were
estimated for key output parameters,
including vaccine benefit (costs and
DALYs averted) and the incremental
cost-effectiveness ratio. Uncertainty
analysis was also used to estimate the
likelihood that vaccination would result
in different levels of cost-effectiveness.
In addition, a contribution-to-variance
analysis was conducted to determine
the contribution of the individual input
parameters to the ICER. 
RESULTS
Vaccination benefits
Table 2 shows the expected rotavirus-
associated events (deaths, hospitaliza-
tions, and outpatient visits) and asso-
ciated medical costs, without and with
vaccination. According to our model,
vaccination of the entire 2003 birth co-
hort would prevent 68% of rotavirus
deaths and 69% of the health care costs
associated with treatment for rotavirus
(Table 2 and Table 3). For the eight
countries studied here, vaccination
would prevent 3 435 deaths for the
2003 annual birth cohort that is vacci-
nated. In addition, vaccination would
prevent US$ 43.4 million in health
care treatment costs and an additional
US$ 16.8 million in societal costs (in-
cluding nonmedical direct costs and
productivity losses). 
Cost-effectiveness analysis
Table 3 shows the results of the cost-
effectiveness analysis, and summa-
rizes the estimated treatment costs,
deaths, and DALYs that would be
averted with vaccination in each coun-
try. The cost of vaccination (adminis-
trative and procurement) is shown for
an assumed vaccine price of US$ 24
per course. The break-even prices,
below which vaccination would be
cost-saving from the health care sys-
tem perspective, range from US$ 1.47
per course in the Dominican Republic
to US$ 10.33 in Chile. The incremental
cost-effectiveness ratio was calculated
as the net cost of vaccination (from the
health care system perspective) di-
vided by the DALY averted. At the
baseline price of US$ 24 per course for
TABLE 1. Input variables and ranges for estimates of cost-effectiveness of rotavirus vaccination of the 2003 birth cohort in eight Latin Amer-
ican and Caribbean countries (all costs reported in 2003 US$)
Country-specific Dominican
input variables (source) Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
2003 birth cohort (35) 726 000 3 471 000 286 000 203 000 206 000 2 285 000 70 000 582 000
5-year risk of hospitalization for 
gastroenteritis (2, 36–41)a 0.093 0.112 0.060 0.065 0.038 0.018 0.065 0.070
Upper and lower boundsb 0.08, 0.11 0.10, 0.13 0.05, 0.07 0.05, 0.08 0.03, 0.04 0.01, 0.02 0.05, 0.08 0.06, 0.08
Proportion of gastroenteritis 
hospitalizations due to rotavirus 
(2, 5, 6, 36, 42–50)a 0.34 0.31 0.47 0.37 0.37 0.40 0.37 0.33
Upper and lower bounds 0.29, 0.39 0.26, 0.36 0.40, 0.54 0.30, 0.44 0.30, 0.44 0.34, 0.46 0.30, 0.44 0.28, 0.38
5-year risk of an outpatient visit for
gastroenteritis (2, 35, 38–40, 51, 52)a 1.38 1.08 0.69 1.08 1.07 1.06 1.13 1.15
Upper and lower bounds 1.17, 1.59 0.81, 1.35 0.59, 0.79 0.81, 1.35 0.91, 1.23 0.90, 1.22 0.96, 1.30 0.98, 1.32
Proportion of gastroenteritis outpatient 
visits due to rotavirus 
(2, 5, 6, 36, 42, 53–56)a 0.26 0.19 0.34 0.25 0.25 0.25 0.25 0.23
Upper and lower bounds 0.22, 0.30 0.16, 0.22 0.29, 0.39 0.20, 0.30 0.20, 0.30 0.20, 0.30 0.20, 0.30 0.20, 0.27
5-year risk of death for gastroenteritis
(per 1 000 births) (35, 57–61)a 0.40 2.30 0.10 5.90 8.70 1.01 1.44 2.00
Upper and lower bounds 0.34, 0.46 1.96, 2.65 0.09, 0.12 5.02, 6.79 7.40, 10.01 0.86, 1.16 1.22, 1.66 1.70, 2.30
Proportion of gastroenteritis deaths
due to rotavirusc 0.34 0.31 0.47 0.37 0.37 0.40 0.37 0.33
Upper and lower bounds 0.27, 0.41 0.25, 0.37 0.38, 0.56 0.30, 0.44 0.30, 0.44 0.32, 0.48 0.30, 0.44 0.26, 0.40
Vaccine coverage (%) (24, 25) 88 96 99 65 92 93 86 68
Average life expectancy (years) (14) 74.2 68.9 75.8 69.6 69.1 74.0 74.1 73.8
a The shape of the distribution was defined as triangular distribution since the true population value was more likely to be closer to the chosen value for the analysis than the minimum or max-
imum values defined by the range. 
b The upper and lower bounds of the distributions were the ones used in the sensitivity and uncertainty analyses.
c The proportion of gastroenteritis mortality attributable to rotavirus was based on the proportion of hospitalizations attributable to it. The shape of the distribution was defined as uniform since
the true population value was equally likely to be any value within the specified range.
TABLE 2. Estimated health burden associated with rotavirus in eight Latin American and Caribbean countries with and without rotavirus
vaccination of the 2003 birth cohort  
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
2003 birth cohort (35) 726 000 3 471 000 286 000 203 000 206 000 2 285 000 70 000 582 000
Without vaccination
Deaths 99 2 475 13 443 663 923 37 384
Hospitalizations 22 956 120 513 8 008 4 882 2 896 16 086 1 684 13 502
Outpatient visits 260 489 712 249 66 924 54 810 55 105 605 525 19 775 153 648
With vaccination
Deaths 33 671 3 224 200 273 13 186
Hospitalizations 7 044 29 386 1 763 2 383 798 4 328 543 6 270
Outpatient visits 92 310 210 598 18 315 28 672 17 911 193 258 7 298 76 994
Averted with vaccination
Deaths 66 1 804 10 219 463 651 24 198
Hospitalizations 15 912 91 127 6 245 2 500 2 099 11 758 1 140 7 232
Outpatient visits 168 179 501 651 48 609 26 138 37 194 412 267 12 477 76 654
the two-dose regimen, the ICER
ranged from US$ 269/DALY in Hon-
duras to US$ 10 656/DALY in Chile.
Cost-effectiveness was also expressed
as cost per death averted, which
ranged from US$ 8 972 per death
averted in Honduras to US$ 422 497
per death averted in Chile. 
Sensitivity and uncertainty analyses
Upper and lower uncertainty limits
generated by the Monte Carlo analysis
are shown in Table 3. These bounds
provide an overall measure of the
likely incremental cost-effectiveness,
given uncertainty in the many input
parameters. An alternative way to
view these results is using “cost-
acceptability” curves. The results in
Figure 1 are based on the cumulative
distribution of the estimated ICERs
from the Monte Carlo analysis. For
each country, Figure 1 shows the like-
lihood (vertical axis) that vaccination
would have an ICER less than a spe-
cific US$/DALY level (horizontal
axis). To estimate the likelihood that
vaccination would meet the standard
for “very cost-effective” (ICER < per
capita GDP) in a given country, a ver-
tical line should be extrapolated from
the horizontal axis at the country’s per
capita GDP to the curve for that coun-
try. The value on the vertical axis at
this point would be the likelihood that
the intervention meets this standard.
For Mexico, for example, the vertical
line would drawn at US$ 6 121, the
per capita GDP for Mexico. Since the
entire curve for Mexico is to the left of
that vertical line, the likelihood that
vaccination will be very cost-effective
for Mexico (ICER < US$ 6 121/DALY)
is more than 95%. For six of the eight
countries, the likelihood that vaccina-
tion would be considered very cost-
effective was greater than 95%. In the
two remaining countries, vaccination
had a greater than 90% chance of being
TABLE 3. Estimated burden of rotavirus and the cost-effectiveness of rotavirus vaccination of the 2003 birth cohort in eight Latin Ameri-
can and Caribbean countries (costs reported in 2003 US$)
Dominican
Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Total medical costs 
Without vaccine 7 061 108 25 332 499 4 641 283 696 601 1 511 679 17 242 669 862 387 5 154 096
With vaccine 2 329 495 6 576 304 1 152 529 352 416 474 980 5 361 075 303 986 2 523 021
Medical costs averted 4 731 614 18 756 195 3 488 755 344 185 1 036 699 11 881 594 558 401 2 631 074
Percent reduction 67% 74% 75% 49% 69% 69% 65% 51%
Vaccination cost a 17 505 312 91 301 184 7 758 036 3 615 430 5 192 848 58 101 152 1 649 480 10 843 824
Medical break-even price 
(US$)b 5.84 4.22 10.33 1.47 4.09 4.18 7.56 5.16
Societal break-even price 
(US$)b 6.86 5.83 12.15 2.59 4.88 7.30 10.36 6.36
DALYsc
Without vaccine 3 549 83 365 543 14 823 22 120 31 768 1 277 13 098
With vaccine 1 192 22 686 142 7 510 6 672 9 438 445 6 345
DALYs averted 2 357 60 679 401 7 313 15 448 22 330 832 6 753
Percent reduction 66% 73% 74% 49% 70% 70% 65% 52%
Number of deaths 
Without vaccine 99 2 475 13 443 663 923 37 384
With vaccine 33 671 3 224 200 273 13 186
Number of deaths averted 66 1 804 10 219 463 651 24 198
Percent reduction 67% 73% 75% 49% 70% 70% 65% 52%
ICER (US$/DALY)d 5 419 1 196 10 656 447 269 2 070 1 311 1 216
4 554 to 1 003 to 8 324 to 1 739 to 1 080 to 1 018 to
Uncertainty range 7 177 1 576 14 348 375 to 589 225 to 359 2 751 1 773 1 622
ICER (US$/death averted) 193 609 40 212 422 497 14 956 8 972 71 052 44 798 41 408
161 099 to 33 574 to 324 308 to 12 521 to 7 476 to 59 315 to 36 665 to 34 443 to 
Uncertainty range 259 118 53 707 585 404 19 764 11 885 94 728 61 296 55 286
a Vaccination cost includes the cost of the vaccine (US$ 24/course) and cost of administering the vaccine.
b Medical and societal vaccine break-even prices per course are the prices at which the cost of vaccination would exactly offset the costs of treatment from the health care system or societal
perspective. At vaccine prices below the break-even threshold, vaccination would be cost-saving.
c DALYs = disability-adjusted life years. 
d ICER =  incremental cost-effectiveness ratio, calculated as the difference in cost with and without the vaccine (vaccination cost minus averted medical costs) divided by the difference in health
outcomes (DALYs or deaths) without and with the vaccine.
considered cost-effective based on the
standard of ICER < three times the per
capita GDP.
The results of one-way sensitivity
analyses are presented in Table 4, and
show the effect of changes in individ-
ual input parameters on the ICER for
vaccination at the baseline price of US$
24 per course. In most countries, the
ICER estimates were most sensitive to
changes in assumptions regarding ro-
tavirus mortality and vaccine efficacy
against mortality. For example, a 20%
change in rotavirus mortality rate re-
sulted in a 15% to 25% change in the
ICER for all eight countries. The ICER
was also significantly affected by the
vaccine price used in the analysis. At 
a price of US$ 16 per course, the ICER
ranged from US$ 161/DALY to US$
4 437/DALY.
The contribution-to-variance analy-
sis revealed the proportion of variance
in the estimated ICER at US$ 24/
course that was attributable to each of
the input variables. In all countries, the
primary sources of uncertainty in
ICER estimates were overall diarrheal
mortality, accounting for 15% to 22%;
the proportion of diarrheal mortality
attributable to rotavirus, accounting
for 19% to 39%; and vaccine efficacy
against mortality, accounting for 20%
to 36%. Uncertainty in the direct costs
of rotavirus hospitalization and out-
patient visits accounted for 1% or less
of the variance in all countries except
Chile, where the costs of hospitaliza-
tion and outpatient visits accounted
for 17% and 2% of the uncertainty in
the estimated ICER, respectively.
DISCUSSION
Benefits of vaccination
The results demonstrate that the in-
corporation of a rotavirus vaccine into
routine vaccination schedules could
effectively reduce the health and eco-
nomic burden associated with rota-
virus gastroenteritis in the eight coun-
tries analyzed here. In terms of
effectiveness, it is estimated that intro-
duction of a vaccination program
would reduce mortality and the med-
ical costs associated with treating ill-
ness by 67% to 72%. These benefits
would be greatest in countries with
the highest disease burden and the
highest vaccine coverage rates. Al-
though vaccine efficacy against mor-
tality was assumed to be the same as
for hospitalized cases (85%), the true
efficacy (and, as a result, effective-
ness) against mortality is unknown.
Because the estimates suggest that
vaccine efficacy would increase with
increasing severity of illness (11), the
assumption of equal vaccine efficacy
against mortality appeared justified,
and was explored further in the sensi-
tivity analysis.
Economic evaluation of vaccination
From the health care system per-
spective, health interventions that re-
sult in negative net costs are excellent
investments since they result in both
improved health and cost savings. In
practice, very few interventions meet
this standard of cost savings (see Table
5). The analysis presented here sug-
gests that although rotavirus vaccina-
tion would not be cost-saving in the
countries studied, it would be very
cost-effective, or at least cost-effective.
The cost-effectiveness analysis com-
pared the net health care costs to the
improvement in health, expressed as
FIGURE 1. Estimated cost-acceptability curves for rotavirus vaccination of the 2003 birth
















































a The vertical axis plots the likelihood that vaccination would have an incremental cost-effectiveness ratio (ICER) less than the
specific US$/DALY (disability-adjusted life year) plotted on the horizontal axis.
the ICER. The interpretation of whether
an intervention is cost-effective de-
pends on the ICER and the standard 
to which it is compared. The standard
should reflect how much a decision-
maker is willing to invest to avert one
DALY or to prevent one death. Sev-
eral standards have been suggested 
to determine whether an intervention
is cost-effective. Using the World
Health Report 2002 standard of cost-
effectiveness (ICER < three times the
per capita GDP) or very cost-effective
interventions (ICER < per capita GDP),
rotavirus vaccination at a vaccine price
of US$ 24/course would be very cost-
effective in six of the countries, and
cost-effective in the two other coun-
tries analyzed here. 
Alternatively, national decisionmak-
ers could compare the cost-effectiveness
of rotavirus vaccination in their country
to the cost-effectiveness of other health
interventions being considered, includ-
ing other strategies for diarrheal pre-
vention, child nutrition, and immuni-
zation. Ideally, the most cost-effective
intervention would be chosen first. Un-
fortunately, country-specific informa-
tion is often unavailable and incom-
plete. The WHO-CHOICE project
provides cost-effectiveness estimates of
diarrheal prevention interventions by
region (34). For developing countries 
in the Region of the Americas, the cost-
effectiveness ratio for point-of-use
water treatment and expansion of oral
rehydration therapy are approximately
US$ 1 000/DALY (34). Although this
estimate may not be applicable for
higher-income countries, the cost-
effectiveness of rotavirus vaccination is
comparable to this standard for most of
the countries analyzed here. For pur-
poses of comparison, additional cost-
effectiveness ratios for other health in-
terventions are shown in Table 5.
However, caution should be used when
comparing across studies, since there
may be differences in the currency base
year and in analytical assumptions. Ide-
TABLE 4. Effect of key variables on the estimated incremental cost-effectiveness ratio of rotavirus vaccination (assuming a cost of US$
24/course) of the 2003 birth cohort in eight Latin American and Caribbean countries (all costs reported in 2003 US$)
Dominican
Variable Argentina Brazil Chile Republic Honduras Mexico Panama Venezuela
Incidence of hospitalization 
for rotavirus
–20% 5 636 1 240 11 526 452 272 2 089 1 362 1 243
Base case 5 419 1 196 10 656 447 269 2 070 1 311 1 216
+20% 5 202 1 151 9 786 442 266 2 051 1 260 1 190
Incidence of outpatient 
visits for rotavirus
–20% 5 607 1 213 11 541 452 279 2 157 1 394 1 268
Base case 5 419 1 196 10 656 447 269 2 070 1 311 1 216
+20% 5 231 1 178 9 773 443 259 1 982 1 228 1 165
Rotavirus mortality rate
–20% 6 677 1 490 12 843 559 336 2 574 1 632 1 516
Base case 5 419 1 196 10 656 447 269 2 070 1 311 1 216
+20% 4 560 998 9 106 373 224 1 731 1 095 1 016
Efficacy against 
rotavirus mortality
70% 6 499 1 448 12 541 543 327 2 503 1 587 1 473
Base (85%) 5 419 1 196 10 656 447 269 2 070 1 311 1 216
94% 4 927 1 082 9 775 405 243 1 875 1 187 1 101
Efficacy against 
rotavirus hospitalization
70% 5 612 1 235 11 434 452 272 2 087 1 356 1 240
Base (85%) 5 419 1 196 10 656 447 269 2 070 1 311 1 216
94% 5 303 1 172 10 190 445 267 2 060 1 284 1 202
Direct medical 
costs, hospitalization
–20% 5 635 1 240 11 525 452 272 2 089 1 362 1 243
Base case 5 419 1 196 10 656 447 269 2 070 1 311 1 216
+20% 5 202 1 151 9 787 442 266 2 051 1 260 1 190
Direct medical 
costs, outpatient visits
–20% 5 604 1 213 11 529 452 279 2 157 1 394 1 268
Base case 5 419 1 196 10 656 447 269 2 070 1 311 1 216
+20% 5 234 1 178 9 784 443 259 1 983 1 228 1 165
Vaccine price
US$ 16/course 3 034 712 4 437 289 161 1 234 674 700
Base 5 419 1 196 10 656 447 269 2 070 1 311 1 216
US$ 32/course 7 804 1 679 16 875 606 377 2 906 1 947 1 732
ally, vaccination should be compared 
to country-specific analyses of the cost-
effectiveness of alternative health in-
vestments being considered in that
country, assuming that the studies use
similar methods.
Although a given intervention may
be considered highly cost-effective, it
may not be affordable because of na-
tional financial constraints. In this situ-
ation, the WHO World Health Report
2002 suggests that external resources
should be made available for the in-
vestment (32). The results presented
here demonstrate that vaccination
would prevent substantial costs asso-
ciated with rotavirus gastroenteritis.
These averted treatment costs could
partially offset the costs of vaccination.
Sensitivity and uncertainty analyses
In addition to providing an overall
assessment of confidence in our esti-
mates of economic burden and cost-
effectiveness, the uncertainty analysis
provides a method for identifying
variables that were likely to signifi-
cantly affect our final estimates of bur-
den and cost-effectiveness. These vari-
ables should be targeted in future
efforts to collect more precise country-
specific estimates. Although improved
estimates of rotavirus-associated mor-
tality and vaccine efficacy against
mortality would allow for more accu-
rate estimates of vaccination cost-
effectiveness, improved estimates of
these parameters may be difficult to
obtain. In spite of these data limita-
tions, the uncertainty analysis showed
that our estimates of cost-effectiveness
were robust, and provided infor-
mation that is potentially useful for
decision-making. 
Limitations of the study
The primary limitations of this
study relate to the incompleteness of
some epidemiological and vaccine ef-
fectiveness parameters identified in
the uncertainty analysis, and the need
to rely on secondary data. Although
uncertainties in these parameters af-
fect the estimated cost-effectiveness 
of vaccination, the magnitude of this
impact was systematically assessed 
in the uncertainty and sensitivity
analyses. The uncertainty analysis in-
cluded those parameters that were ex-
pected to significantly influence cost-
effectiveness; however, some factors
were not considered. In particular, this
analysis did not explicitly consider
two factors that may impact the results
of the study. First, delays in the timing
of routine vaccinations might preclude
the prevention of rotavirus-associated
events occurring very early in child-
hood. Second, it is not known whether
those children who are at the greatest
risk of dying from rotavirus infection
have the same vaccination coverage as
the general population. 
A final study limitation is that this
analysis considered the direct effects
of vaccination but did not consider the
potential indirect protective effect of
herd immunity for persons unpro-
tected by the vaccine. Three groups of
people could benefit if vaccination
provided herd immunity: children
prior to receiving the first dose of the
vaccine, children who are not vacci-
nated, and children who are vacci-
nated but in whom immunization is
unsuccessful. Unfortunately, there are
no data on the magnitude of the herd
immunity that might be conferred by
partial penetration of vaccination in a
population, although partial vaccina-
tion is a plausible scenario since chil-
dren might be exposed to the vaccine
strain shed by vaccinated children,
and thus might be less exposed to the
wild-type rotavirus. By analogy to
other vaccine-preventable infectious
diseases, the effect of herd immunity
might be substantial, and might offset
gaps in the delivery of full-course on-
time vaccination. Therefore, herd im-
munity might contribute to the cost-
effectiveness of rotavirus vaccination. 
In conclusion, given the limits to fi-
nancial resources available from na-
tional governments and donors, vacci-
nation is potentially a cost-effective
option for improving child health and
TABLE 5. Comparison of the cost-effectiveness of various health interventions 
Cost-effectiveness
Intervention Location ratio (US$/DALY)a Source
Diarrheal disease
Rotavirus vaccination (US$ 24/course) 8 Latin American countries 269 to 10 656 Current study
Rotavirus vaccination (US$ 16/course) 8 Latin American countries 161 to 4 437 Current study
Oral rehydration therapy expansion to 50% Latin America (low mortality)b 1 085 (34)
Point of use water treatment Latin America (low mortality)b 1 092 (34)
Water supply and sanitation Global 13 00 (62)
Hygiene education Global 9 to 150 (62)
Breast-feeding promotion Brazil, Honduras, Mexico 12 to 19 (63)
Child health
Zinc supplementation (children < 5 yr) Latin America (low mortality)b 102 (34)
Vitamin A supplementation Latin America (low mortality)b 521 (34)
Integrated management of childhood illness Global 40 to 140 (62)
a Costs have been converted to 2003 US$ for comparison; DALY = disability-adjusted life year. 
b Countries are classified by the World Health Organization according to region and mortality stratum. All eight countries selected for this study are classified as having low child and low adult
mortality. Within Latin America, the following countries are classified as having high child and high adult mortality: Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, and Peru (64).
reducing mortality in the Latin Ameri-
can and Caribbean countries analyzed
here. The results of this study suggest
that immunization of the entire annual
birth cohort with an effective rota-
virus vaccine could greatly reduce the
disease burden and costs associated
with rotavirus gastroenteritis. In addi-
tion, vaccination is a potentially cost-
effective investment compared to
other options to control childhood gas-
troenteritis across a range of vaccine
prices. 
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cessed 18 January 2005.
Objetivos. Estimar los costos, los beneficios y la efectividad en función del costo de
la vacunación contra la gastroenteritis por rotavirus en ocho países de América Latina
y el Caribe: Argentina, Brasil, Chile, Honduras, México, Panamá, República Domini-
cana y Venezuela.
Métodos. Se elaboró un modelo económico para estimar la efectividad en función
del costo de la vacunación, desde la perspectiva del sistema de salud, a partir de las
constancias epidemiológicas nacionales oficiales y publicadas, los estimados de cos-
tos específicos de cada país y los datos de eficacia de la vacuna. El modelo se aplicó a
los primeros cinco años de vida de la cohorte de nacidos en 2003 en cada uno de esos
países. La principal medida de salud fueron los años de vida ajustados por discapaci-
dad (AVAD) y la principal medida sintética fue el costo incremental por AVAD evi-
tado. Se empleó una tasa de descuento de 3% para el pronóstico de los costos y bene-
ficios. El impacto de la incertidumbre relacionada con las variables clave sobre la
efectividad en función del costo se realizó mediante el análisis de sensibilidad.
Resultados. Según los estimados obtenidos mediante el modelo económico, la va-
cunación podría evitar más de 65% de las consultas médicas, de las muertes y del
costo de tratamiento asociados con la gastroenteritis por rotavirus en los ocho países
analizados. Con un costo total de US$ 24,00 (por las dos dosis de la vacuna), la razón
incremental de la efectividad en función del costo varió entre US$ 269/AVAD en
Honduras y US$ 10 656/AVAD en Chile. Las razones de la efectividad en función
del costo fueron sensibles a las diversas hipótesis sobre el precio de la vacuna, la mor-
talidad y la eficacia de la vacuna.
Conclusiones. La vacunación permitiría reducir eficazmente la carga de morbilidad
y los costos de la atención sanitaria de la gastroenteritis por rotavirus en los países
analizados de América Latina y el Caribe. Desde la perspectiva de los sistemas de
salud, se prevé que la vacunación universal de todos los niños será efectiva en fun-
ción del costo, según los estándares vigentes en la actualidad.
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